comparemela.com

Latest Breaking News On - Regen biopharma - Page 10 : comparemela.com

Regen BioPharma, Inc Progresses Its DuraCAR Therapeutic

/PRNewswire/ Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its.

David koosDavidr koosRegen biopharmaPrnewswire regen biopharma incRegen biopharma incInitial designRegen biopharma inc

Regen BioPharma, Inc to Present at the Emerging Growth Conference on November 9, 2022

Regen BioPharma, Inc to Present at the Emerging Growth Conference on November 9, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David koosRegen biopharmaPrnewswire regen biopharma incRegen biopharma incContact informationregen biopharma inc davidr koosEmerging growthEmerging growth conferenceEmerging growth conference theBiopharma inc davidChief executive

Regen BioPharma, Inc Explores the CAR-T Therapeutic Space

/PRNewswire/ Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T.

Davidr koosRegen biopharmaPrnewswire regen biopharma incRegen biopharma incRegen biopharma inc

Regen BioPharma, Inc Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer

/PRNewswire/ Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled.

United statesDavid koosDavidr koosRegen biopharmaPrnewswire regen biopharma incRegen biopharma incTrademark officeNovel approach expectedExpand usingTumors through augmentationChemokine responsivenessActivation dependent chemokineUnited states patentRegen biopharma inc

Regen BioPharma, Inc Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer

/PRNewswire/ Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled.

United statesDavid koosDavidr koosRegen biopharmaPrnewswire regen biopharma incRegen biopharma incTrademark officeNovel approach expectedExpand usingTumors through augmentationChemokine responsivenessActivation dependent chemokineUnited states patent

vimarsana © 2020. All Rights Reserved.